The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISTH 2023 | Low-dose emicizumab prophylaxis in patients with severe hemophilia A
In this video, Rucha Patil, PhD, ICMR-National Institute of Immunohematology, Mumbai, India, discusses the results of a study evaluating the safety and efficacy of low-dose emicizumab prophylaxis in patients with severe hemophilia A. This interview took place at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Montréal, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
